My Cancer Advisor

Tarceva, also known as Erlotinib, is an oral form of cancer therapy taken once a day that is approved by the FDA as a “second line” (i.e. backup) for patients with non-small cell lung cancer where standard chemotherapy has failed. It is an important drug as part of an initial therapy, along with gemcitabine, in patients with metastatic pancreas cancer.

This is a seven minute product description, produced by the manufacturers Genentech and OSI pharmaceutical companies, that is informative for those patients who want more details about how the drug works and some of its side effects. For more details on the web, you can go to http://www.tarceva.com.